Treatment with monoclonal antibodies instead of high-dose chemotherapy might help children with primary immunodeficiencies get the most from stem cell transplants, British researchers reported. Monoclonal antibodies target only the immune cells that cause rejection and not other body tissue, allowing patients to recover more quickly and avoid the toxicity from chemotherapy, the study found.

Full Story:

Related Summaries